Advances in the pharmacological management of Parkinson disease

Journal of Neural Transmission, Supplement

Volumn , Issue 64, 2003, Pages 65-78

  Tolosa, E ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BENSERAZIDE; CABERGOLINE; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; OLANZAPINE; ONDANSETRON; PERGOLIDE; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; ROPINIROLE; SELEGILINE; TACRINE; TOLCAPONE; ANTIPARKINSON AGENT;

AGRANULOCYTOSIS; AKATHISIA; BEHAVIOR; CLINICAL TRIAL; CONFERENCE PAPER; CONFUSION; CONSTIPATION; DEGENERATIVE DISEASE; DELUSION; DIARRHEA; DYSKINESIA; DYSTONIA; ERYTHROMELALGIA; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HALLUCINOSIS; HUMAN; HYPOTENSION; LIVER TOXICITY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; SALIVATION DISORDER; SOMNOLENCE; TARDIVE DYSKINESIA; URINE COLOR; VOMITING; REVIEW;

ANTIPARKINSON AGENTS; HUMANS; PARKINSON DISEASE;

EID: 0042243550     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6020-6_4     Document Type: Conference Paper

References (101)

1. Aarsland D, Larsen JP, Lim NG, Tandberg E (1999) Olanzapine for psychosis in patients with Parkinson's disease with and without dementia. J Neuropsychiatry Clin Neurosci 11: 392-394
2. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen (2001) Risk of dementia in Parkinson's disease. A community-based, prospective study. Neurology 56: 730-736
3. Adler CH, Sethi KD, Hauser RA, et al (1997) Ropinirole for the treatment of early Parkinson's disease. Neurology 49: 393-399
4. Adler CH, Singer C, O'Brien C, hauser RA, Lew MF, Marek KL, et al (1998) Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson's disease treated with levodopa-carbidopa. Arch Neurol 55: 421-428
5. Agid Y, Ahlskog A, Albanese A, et al (1999) Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov Disord 14: 911-913
6. Boller F, Mizutani T, Roessmann U, Gambetti P (1980) Parkinsons disease, dementia and Alzheimer disease: clinicopathological correlations. Ann Neurol 7: 329-335
7. Borison RL (1995) Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol 15 [Suppl 1]: 24-29
8. Borison RL, Rathiraja AP, Bruce I, et al (1992) Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 28: 213-218
9. Brandstäder D, Oertel WH (2002) Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology 58: 160-161
10. Calopa M, Tolosa E, Ferrer I, et al (2002) In: Tolosa E, Schultz J, McKeith I, Ferrer I (eds) Neurodegenerative disorders asociated with alpha synuclein pathology. Medicina STM Editores, Barcelona, pp 127-135
11. Cash R, Donnis T, L'Heureux R, Raisman R, Javoy-Agid F, Scatton B (1987) Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus. Neurology 37: 42-46
12. Cotzias GC, Van Woert MH, Schiffer LM (1970) Aromatic amino acids and modification of parkinsonism. N Engl J Med 282: 31-33
13. Dewey RB, O'Suilleabhain PE (2000) Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology 55: 1753-1754
14. Factor SA, Brown D (1992) Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord 7: 125-131
15. Factor SA, Friedman JH (1997) The emerging role of clozapine in the treatment of movement disorders. Mov Disord 12: 483-496
16. Factor SA, Brown D, Molho ES, Podskalny GD (1994) Clozapine: a 2-year open trial in PD patients with psychosis. Neurology 44: 544-546
17. Factor SA, Molho ES, Podskalny GD, Brown D (1995) Parkinson's disease: drug-induced psychiatric states. In: Weiner WJ, Lang AE (eds) Advances in neurology, vol 65. Raven Press, New York, pp 115-138
18. Fahn S (1974) On-off phenomenon with levodopa therapy in parkinsonism. Neurology 24: 431-441
19. Fernández HH (2000) Quetiapine for 1-dopa induced psychosis in PD. Neurology 55: 899
20. Fernandez HH, Durso R (1998) Clozapine for dopaniergic-induced paraphilias in Parkinson's disease. Mov Disord 13: 597-598
21. Fernández HH, Friedman JH, Jacques C, Rosenfeld M (1999) Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 14: 484-487
22. Friedman JH (1998) Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 50: 1195-1196
23. Friedman JH, Lannon MC (1989) Clozapine in the treatment of psychosis in PD. Neurology 39: 1219-1221
24. Friedman JH, Goldstein S, Jacques C (1998) Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: results of an open label pilot study. Clin Neuropharmacol 5: 285-288
25. Gerlach J, Peacock L (1994) Motor and mental side effects of clozapine. J Clin Psychiatry 55 [Suppl B]: S107-S109
26. Goetz C (1998) Influence of COMT inhibition on levodopa pharmacology and therapy. Neurology 50 [Suppl 5]: 26-30
27. Goetz CG, Stebbins GT (1993) Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 43: 2227-2229
28. Goetz CG, Vogel C, Tanner CM, Stebbins GT (1998) Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 51: 811-814
29. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ (2000) Olanzapine and clozapine. Comparative effects on motor function in hallucinating PD patients. Neurology 55: 748-749
30. Goodwin FK (1971) Psychiatric side effects of 1-dopa in man. JAMA 218: 1915-1920
31. Graham JM, Sussman JD, Ford KS, Sagar HJ (1998) Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note. J Neurol Neurosurg Pschiatry 65: 774-777
32. Hakim A, Mathieson G (1979) Dementia in Parkinson disease: a neuropathologic study. Neurology 29: 1209-1214
33. Halperin JR, Murphy B (1992) Extrapyramidal reaction to ondansetron. Cancer 69: 1275
34. Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, De Teresa R, Thal L, Pay MM, Hofstetter R, Klauber M, Rice V, Butters N, Alford M (1990) The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 40: 1-8
35. Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM-Y, Clark CM, Glosser G, Stern MB, Gollomp SM, Arnold SE (2000) α-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 54: 1916-1921
36. Hutchinson M, Fazzini E (1996) Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry 61: 324-325
37. Keränen T, Gordin A, Harjola VP, Karlsson M, Korpela K, y cols (1996) The effect of cathecol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 50: 47-55
38. Kieburtz K, Shoulson I, McDermontt M, et al (1997) Safety and efficacy of pramipexole, in early Parkinson disease. A randomized dose-ranging study. JAMA 278: 125-130
39. Klawans HL (1986) Individual manifestations of Parkinson's disease after ten or more years of levodopa. Mov Disord 1: 187-192
40. Krupp P, Barnes P (1992) Clozapine-associated agranulocytosis: risk and aetiology. Br J Psychiatry 160 [Suppl 17]: 38-40
41. Kurth MC, Adler CH (1998) COMT inhibition: a new strategy for Parkinson's disease. Neurology 50 [Suppl 5]: 3-14
42. Kuruma I, Bartholini G, Tissot R, Pletscher A (1971) The metabolism of L-3-Omethyldopa, a precursor in man. Clin Pharmacol Ther 12: 678-682
43. Lennox G, Lowe J, Morrell K, Landon M, Mayer RJ (1989) Anti-ubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease. J Neurol Neusosurg Psychiatry 52: 67-71
44. Lew MF, Waters CH (1993) Clozapine treatment of parkinsonism with psychosis. J Am Geriatr Soc 41: 669-671
45. Livingston MG (1994) Risperidone. Lancet 343: 457-460
46. Männistö PT (1994) Clinical potential of catechol-O- methyltransferase (COMT) inhibitors as adjuvants in Parkinson's disease. CNS Drugs 1: 172-179
47. Männistö PT, Kaakkola S (1989) New selective COMT inhibitors: useful adjuncts for Parkinson's disease? Trends Pharmacol Sci 10: 47-55
48. Männistö PT, Tuomainen P, Tuomainen PK (1992) Different in vivo properties of three new inhibitors of cathechol-O-methyl transferase in rat. Br J Pharmacol 105: 569-574
49. Manson AJ, Schrag A, Lees AJ (2000) Low-dose olanzapine for levodopa induced dyskinesias. Neurology 55: 795-799
50. Marsden CD, Parkes JP, Quinn N (1982) Fluctuations of disability in Parkinson's disease. In: Marsden CD, Fahn S (eds) Movement disorders. Butterworth, London
51. Matheson AJ, Lamb HM (2000) Quetiapine. A review of its clinical potential in the management of psychotic symptoms in Parkinson's disease. CNS Drugs 14: 157-172
52. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A (2000) Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet 356: 2031-2036
53. Meco G, Alessandria A, Binfati V, Giustini P (1994) Risperidone for hallucinations in 1-dopa-treated PD patients. Lancet 343: 1370-1371
54. Megens AAHP, Awouters FHL, Schotte A, et al (1994) Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacol 114: 9-23
55. Meltzer HY (1993) New drugs for the treatment of schizophrenia. Psychiatr Clin North Am 16: 365-385
56. Meltzer HY, Matsubara S, Lee J-C (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin-2 pKi values. J Pharmacol Exp Ther 251: 238-246
57. Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioural pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 262: 545-551
58. Moskovitz C, Moses H, Klawans H (1978) L-dopa induced psychosis: a kindling phenomena. Am J Psychiatry 135: 6-10
59. Nausieda P, Tanner C, Klawans H (1983) Serotonergically active agents in the treatment of the 1-dopa induced psychosis. In: Fahn S, Calne DB, Shoulson I (eds) Experimental therapeutics of movement disorders. Raven Press, New York, pp 23-32 (Adv Neurol 37)
60. Nutt JG, Fellman JH (1984) Pharmacokinetics of levodopa. Clin Neuropharmacol 7: 35-49
61. Nutt JC (1990) Levodopa induced dyskinesia. Neurology 40: 340-345
62. Ostergaard K, Dupond E (1988) Clozapine treatment of drug-induced psychotic symptoms in late stages of PD. Acta Neurol Scand 78: 349-350
63. Papavasiliou PS, Cotzias GC, Duby SE, et al (1972) Levodopa in parkinsonism: potentiation of central effets with a peripheral inhibitor. N Engl J Med 285: 8-14
64. Parkinson Study Group (1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 4 [Suppl 3]: 3-11
65. Parkinson Study Group (1999) Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 340: 757-763
66. Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson's disease. JAMA 284: 1931-1938
67. Parsa MA, Bastani B (1998) Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 10: 216-219
68. Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR, Bloxham CA, Blessed G, Fairbairn A, Tomlinson BE, Perry RM (1985) Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 48: 413-421
69. Perry RH, Irving D, Blessed G, Perry EK, Fairbairn A (1989) Senile dementia of Lewy body type and spectrum of Lewy body disease Lancet i: 1088
70. Pfeiffer RF, Kang J, Graber B, Hofman R, Wilson J (1990) Clozapine for psychosis in Parkinson's disease. Mov Disord 5: 239-242
71. Quinn NP, Rossor MN, Marsden CD (1986) Dementia and Parkinson's disease: pathological and neurochemical consequences. Br Med Bull 42: 86-90
72. Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E, Pedder S (1997) Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 49: 1066-1071
73. Rascol A, Montastruc JL, Guirard-Chaumeil B, Clanet M (1982) Bromocriptine as first treatment of Parkinson's disease. Long-term results. Rev Neurol 138: 402-408
74. Rascol O, Brooks DJ, Korczyn AD, et al (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 342: 1484-1491
75. Reading PJ, et al (2001) Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 16: 1171-1195
76. Rich SS, Friedman JH, Ott BR (1995) Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 56: 556-559
77. Rinne JO, Rummukainen J, Paijarvi L, Rinne UK (1989) Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 25: 146-151
78. Rinne UK (1983) Problems associated with long term levodopa treatment of Parkinson's disease. Acta Neurol Scand 95: 19-26
79. Rinne UK, Bracco F, Chouza C, et al (1997) Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology 48: 363-368
80. Rinne UK, Bracco F, Chouza C, et al (1998) Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PkDS009 study Group. Drugs 55 [Suppl 1]: 23-30
81. Rinne UK, Larsen JP, Siden A, Worm-Petersen J (1998) The Nomecomt Study Group. Entacapone enhances the response to levodopa in Parkinsonian patients with motor fluctuations. Neurology 51: 1309-1314
82. Sánchez-Ramos JR (1997) High dose pergolide monotherapy for the treatment of severe dyskinesias in Parkinson's disease. In: Olanow WC, Obeso JA (eds) Beyond the decade of the brain, vol 2. Dopamine agonists in early Parkinson's disease. Wells Medical Limited, UK, pp 217-232
83. Sethi KD, O'Brien CF, Hammerstad JP, et al (1998) Ropinirole for the treatment of early Parkinson's disease-a 12-month experience. Arch Neurol 55: 1211-1216
84. Shannon KM, Bennett JP Jr., Friedman JH (1997) Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 49: 724-728
85. Tagliavini F, Pilleri G, Bouras C, Constantinidis J (1992) The basal nucleus of Meynert in idiopathic Parkinson's disease. Acta Neurol Scand 69: 20-28
86. Tolosa E (1998) Current Parkinson's disease therapy. Levodopa-The Gold Standard. Clin Neuropharmacol 21 [Suppl 1]: S1-S4
87. Tolosa E (1999) Levodopa-induced dyskinesias and fluctuations in Parkinson disease. PIL, Paris
88. Tolosa E, Marin C (1997) Dopamine agonists in Parkinson's disease: a clinical review. In: Olanow WC, Obeso JA (eds) Beyond the decade of the brain, vol 2. Dopamine agonists in early Parkinson's disease. Wells Medical Limited, UK, pp 143-161
89. Tolosa E, Martín W, Cohen H, Jacobson J (1975) Patterns of clinical response and plasma dopa levels in Parkinson's disease. Neurology 25(2): 177-183
90. Tolosa E, Blesa R, Bayes A, et al (1987) Low-dose bromocriptine in early phases of Parkinson's disease. Clin Neuropharmacol 10: 169-174
91. Tolosa E, Valldeoriola F, Martí MJ (1994) New and emerging strategies for improving levodopa treatment. Neurology 44: 535-544
92. Trosch RM, Friedman JH, Lannon MC, Pahwa R, Smith D, Seeberger LC, O'Brien CF, LeWitt PA, Koller WC (1998) Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Mov Disord 13: 377-382
93. Weiner WJ, Minagar A, Shulman LM (2000) Quetiapine for 1-dopa induced psychosis in PD. Neurology 54: 1538
94. White A, Corn TH, Feetham, Faulconbridge C (1991) Ondansetron in treatment of schizophrenia. Lancet 337: 1173
95. Wilson JA, Smith RG (1989) The prevalence and aetiology of long term L-dopa side effects in elderly parkinsonian patients. Age Ageing 18: 11-16
96. Wolters EC, Hurwitz TA, Mak E, et al (1990) Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 40: 832-834
97. Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmans PL (1997) Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 47: 1085-1087
98. Workman RH Jr, Orengo CA, Bakey AA, Molinari VA, Kunik ME (1997) The use of risperidone for psychosis and agitation in demented patients with PD. J Neuropsychiatry Clin Neurosci 9: 594-597
99. Zoldan J, Friedberg G, Goldberg-Stern, Melamed E (1993) Ondansentron for hallucinosis in advanced Parkinson's disease. Lancet 341: 562-563
100. Zoldan J, Friedberg G, Weizman A, Melamed E (1996) Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Parkinson's disease. Lippincot-Raven, Philadelphia, pp 541-544 (Adv Neurol 69)
101. Zweig RM, Cardillo JE, Cohen M, Giere S, Hedreen JC (1993) The locus ceruleus and dementia in Parkinson's disease. Neurology 43: 986-991